Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022
- PMID: 35980866
- PMCID: PMC9400529
- DOI: 10.15585/mmwr.mm7133e1
Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022
Abstract
As SARS-CoV-2, the virus that causes COVID-19, continues to circulate globally, high levels of vaccine- and infection-induced immunity and the availability of effective treatments and prevention tools have substantially reduced the risk for medically significant COVID-19 illness (severe acute illness and post-COVID-19 conditions) and associated hospitalization and death (1). These circumstances now allow public health efforts to minimize the individual and societal health impacts of COVID-19 by focusing on sustainable measures to further reduce medically significant illness as well as to minimize strain on the health care system, while reducing barriers to social, educational, and economic activity (2). Individual risk for medically significant COVID-19 depends on a person's risk for exposure to SARS-CoV-2 and their risk for developing severe illness if infected (3). Exposure risk can be mitigated through nonpharmaceutical interventions, including improving ventilation, use of masks or respirators indoors, and testing (4). The risk for medically significant illness increases with age, disability status, and underlying medical conditions but is considerably reduced by immunity derived from vaccination, previous infection, or both, as well as timely access to effective biomedical prevention measures and treatments (3,5). CDC's public health recommendations change in response to evolving science, the availability of biomedical and public health tools, and changes in context, such as levels of immunity in the population and currently circulating variants. CDC recommends a strategic approach to minimizing the impact of COVID-19 on health and society that relies on vaccination and therapeutics to prevent severe illness; use of multicomponent prevention measures where feasible; and particular emphasis on protecting persons at high risk for severe illness. Efforts to expand access to vaccination and therapeutics, including the use of preexposure prophylaxis for persons who are immunocompromised, antiviral agents, and therapeutic monoclonal antibodies, should be intensified to reduce the risk for medically significant illness and death. Efforts to protect persons at high risk for severe illness must ensure that all persons have access to information to understand their individual risk, as well as efficient and equitable access to vaccination, therapeutics, testing, and other prevention measures. Current priorities for preventing medically significant illness should focus on ensuring that persons 1) understand their risk, 2) take steps to protect themselves and others through vaccines, therapeutics, and nonpharmaceutical interventions when needed, 3) receive testing and wear masks if they have been exposed, and 4) receive testing if they are symptomatic, and isolate for ≥5 days if they are infected.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Figures

Similar articles
-
Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage.MMWR Morb Mortal Wkly Rep. 2021 Jul 27;70(30):1044-1047. doi: 10.15585/mmwr.mm7030e2. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34324480 Free PMC article.
-
COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):125-131. doi: 10.15585/mmwr.mm7104e1. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35085222 Free PMC article.
-
Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.MMWR Morb Mortal Wkly Rep. 2020 Dec 11;69(49):1860-1867. doi: 10.15585/mmwr.mm6949e2. MMWR Morb Mortal Wkly Rep. 2020. PMID: 33301434 Free PMC article.
-
Pathogenesis-directed therapy of 2019 novel coronavirus disease.J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10. J Med Virol. 2021. PMID: 33073355 Review.
-
Novel approaches for preventing COVID-19 infection in immunocompromised patients with hematologic malignancies.Expert Rev Hematol. 2025 Jan;18(1):39-46. doi: 10.1080/17474086.2024.2436973. Epub 2024 Dec 3. Expert Rev Hematol. 2025. PMID: 39610334 Review.
Cited by
-
Cost-effective in-house COVID-19 reverse transcription-polymerase chain reaction testing with yeast-derived Taq polymerase.Ann Thorac Med. 2024 Apr-Jun;19(2):165-171. doi: 10.4103/atm.atm_180_23. Epub 2024 Apr 25. Ann Thorac Med. 2024. PMID: 38766371 Free PMC article.
-
Preparedness for the next wave of COVID-19 in the Republic of Korea.Osong Public Health Res Perspect. 2022 Aug;13(4):239-241. doi: 10.24171/j.phrp.2022.0240. Epub 2022 Aug 31. Osong Public Health Res Perspect. 2022. PMID: 36097745 Free PMC article. No abstract available.
-
Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 - United States, January-July 2022.MMWR Morb Mortal Wkly Rep. 2022 Oct 28;71(43):1359-1365. doi: 10.15585/mmwr.mm7143a2. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36301738 Free PMC article.
-
Association Between Hypertension and Diabetes Control and COVID-19 Severity: National Patient-Centered Clinical Research Network, United States, March 2020 to February 2022.J Am Heart Assoc. 2023 Nov 7;12(21):e030240. doi: 10.1161/JAHA.122.030240. Epub 2023 Oct 18. J Am Heart Assoc. 2023. PMID: 37850404 Free PMC article.
-
Dynamic contact networks of residents of an urban jail in the era of SARS-CoV-2.Epidemics. 2024 Jun;47:100772. doi: 10.1016/j.epidem.2024.100772. Epub 2024 May 15. Epidemics. 2024. PMID: 38776713 Free PMC article.
References
-
- CDC. Science brief: indicators for monitoring COVID-19 Community Levels and making public health recommendations. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/indicat... - PubMed
-
- CDC. Science brief: SARS-CoV-2 transmission. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-co...
-
- CDC. Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine...
-
- Christie A, Brooks JT, Hicks LA, Sauber-Schatz EK, Yoder JS, Honein MA; CDC COVID-19 Response Team. Guidance for implementing COVID-19 prevention strategies in the context of varying community transmission levels and vaccination coverage. MMWR Morb Mortal Wkly Rep 2021;70:1044–7. 10.15585/mmwr.mm7030e2 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous